Tivic(TIVC)

Focus: Tivic (now Valion Bio) is a public biotech company pivoting from bioelectronics devices to late-stage biopharma, focusing on entolimod and CDMO capabilities. The company operates at a small scale with minimal revenue generation and negative cash burn.

Profile data last refreshed 7h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

About Tivic

AI assessmentNot Hiring

No open roles listed right now. Follow Tivic to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$1M

Pipeline & Clinical Trials

Microcurrent TENS device

Chronic Rhinosinusitis

N/A

Clinical Trials (1)

NCT05198518Microcurrent Device (TIVIC Health)

N/A

Help build intelligence for Tivic

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage pivot opportunity: the company is transitioning from medical devices to late-stage biopharma with entolimod, offering exposure to drug development phases earlier careers typically cannot access
Public company status provides liquidity, equity transparency, and institutional credibility that pre-revenue biotechs lack
CDMO expansion signals diversified revenue strategy beyond pipeline, reducing single-program dependency risk

Watch Out For

Severe cash burn: company lost $8.2M in FY2024 on only $1M revenue, with cash declining from $3M to $2M; sustainability is a 12–18 month question at current burn rate
No active hiring: zero open positions despite recent rebrand suggests either post-restructuring stasis or delayed ramp post-pivot; unclear org capacity for new talent
Device-to-drug transition execution risk: three sinus/rhinosinusitis programs show early-stage portfolio with no Phase 1+ clinical data; clinical success is unproven and capital requirements are high

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Publications: 2 in PubMed

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

R&D Spend

$1M21%

Net Income

-$6M

Cash

$2M

Source: SEC 10-K Filing

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(2)

Recent peer-reviewed publications with author affiliations at this company

Correction to: Prospective trial examining safety and efficacy of microcurrent stimulation for the treatment of sinus pain and congestion.

Bioelectronic medicine

2020

PMID:32232222

Prospective trial examining safety and efficacy of microcurrent stimulation for the treatment of sinus pain and congestion.